ALSO NOTED: New York pumps biotech complex; Investors focus on NZ biotech; Questions about anti-TNF safety;and much more...

> The New York Times examines New York State's $43 million effort to develop a biotech hub on Long Island. Most of that money has gone into the Broad Hollow Bioscience Park on the Farmingdale State College campus. Report

> ZymoGenetics has launched a Phase II/III study of Atacicept which it is developing with Merck KGaA as a new therapy for systemic lupus erythematosus. Release

> New Zealand Venture Investment Fund and Pacific Channel Limited are partnering up to make new investments in New Zealand biotech companies. Report

> American Oriental Bioengineering announced today that it has withdrawn its convertible preferred stock offering, citing market conditions. Release

> Intercytex has closed recruitment for the Phase III trial of ICX-PRO in venous leg ulcers. Report

> Anti-trust officials have given Intercell AG an early green light for its planned acquisition of Iomai. Report

> Novartis CEO Daniel Vasella has a knack for the quotable quote. Here's the latest: "Teva is better than we are, and that's hard to take." Report

> In a development sure to spawn headlines across the country, the FDA is looking into a possible link between autoimmune drugs such as Remicade and Humira--known as TNF blockers for their action against tumor necrosis factor--and childhood cancers. Report

> Are new warnings on their way for epilepsy meds? The FDA and drugmakers are hashing out the issue. Report

> The AIDS Vaccine Research Subcommittee of the NIH has OK'd a new AIDS vaccine trial, prompting some skeptics to caution against plunging back into trials so soon after a Merck program misfired. Report

> Switzerland's Mymetics says that its experimental malaria vaccine could be ready for marketing as early as 2014. Report

And Finally... Scientists have been studying the genetic reason why some members of four Turkish families can only walk on all fours. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.